Moderna CEO and AstraZeneca Official Reveal Shocking

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
337
Moderna CEO and AstraZeneca Official Reveal Shocking Secrets to COVID Vaccines After Romanian MEP Cristian Terheș Grills Them

On Monday, Romanian Member of the European Parliament Cristian Terheș grilled Moderna CEO Stéphane Bancel and AstraZeneca executive vice-president Iskra Reic surrounding the safety and efficacy of the vaccines and overly secretive contracts.

Several concerns were asked by MEP Terhes of the executives, such as whether or not they had decoded the DNA of the COVID virus, why they did not take responsibility for the side effects from the vaccines, and when they would release the unredacted contracts with the European Commission.

The first set of questions was for both AstraZeneca and Moderna. Below are the questions asked by Terhes:

First question: I would like to know the date, if possible, when you decoded the entire DNA sequence of this virus or did you rely solely on the sequence provided by the Chinese government?

Second question: Have you tested whether the vaccine stops the spread of the virus or not? Because the data clearly shows that your products are not stopping the spread of this virus.

Third question: Have you had people die during the human trials, and if so, what was the disease they died from?

The second set of questions was directed to Moderna CEO Bancel, below is the excerpt:

You stated here that you relied on the sequence provided to you by the Chinese government when you developed your vaccine. I have here an answer from EMA, which shows for every vaccine the kind of tests that were done.
So in the case of Moderna, for example, you provided data showing that you tested these vaccines since 2017, 2018, and 2019. So how are you able to test these vaccines back then when we found out about this virus in December of 2019?

The contract you mentioned here that there are some secrets or some confidential information in these contracts that should protect your interests. Now, the question that I addressed to you is, what about the interests of us and the interests of the European citizens?

Because this is how some of the pages from the contract between Moderna and the European Commission is showing. So I’m asking you, do you think this is fair to all of us to talk about these vaccines, to talk about boosters, to talk about medical products when we don’t know the clauses of these contracts? So the direct question to you, Mr. Bonsel, is when are you going to fully publish the contracts that you have both with the European Commission and with the member states of the European Union?

Another question, the issue of liabilities. You were asked by our colleagues here about the liabilities and you avoided to answer this question. So my question is why are you pushing the liabilities on the state and on the people who receive these vaccines? I think I might have adverse effect, why do you get all the profits?

Nevertheless, the bivalent boosters. This is the last question. You just stated here that these boosters were requested by the US government who also approved the boosters without trials on humans.

So I’m asking you, do you think this is fair? Do you think we can go and ask the European citizens to be vaccinated with some medical products that were not properly tested or not at all tested in humans?

In their responses regarding liability, executives of Moderna and AstraZeneca said that they produced the vaccines at the request of the states and governments, who asked them to make the vaccines quickly, therefore they sought protection from them for payment of possible damages and compensations, according to MEP’s Facebook post.

“On liability for adverse effects, as all manufacturers have done, we wanted, governments wanted quick approval of a vaccine. And so for a conditional approval, it was important to give us some guarantees in terms of [compensation/damages], because we cannot have our cake and eat it too. They wanted the vaccine quickly. They didn’t give the manufacturers time to have long-term studies because of the nature of a pandemic,” Moderna CEO Stéphane Bancel answered the question MEP Cristian Terheș.

“The liability and indemnification clause was discussed and agreed upon with many governments around the world because everyone wanted to see how we could speed up the production and delivery of vaccines. And, again, as I mentioned earlier, this is considered to be standard practice in emergency situations, and equally [the practice] that protects and supports everyone to move forward with the greatest speed and to do the best they can in terms of production and manufacturing [vaccines],” AstraZeneca executive vice president Iskra Reic answered the same question.

Bancel also admitted that Moderna used the sequence published by the Chinese government online and tested by many scientists in academic labs and government labs for the design of the vaccine.

Back in March, Pfizer CEO Albert Bourla admitted during his interview with WaPo that the “mRNA vaccine” technology was not sufficiently proven when they launched it. He said the experts “convinced him” but he wasn’t sure. He said they’ve been working for the mRNA since 2018.

https://www.thegatewaypundit.com/2022/09/must...es-grills/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 235

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 347

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 276

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 183

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 238

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 522

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 271

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 451

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 202

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 104

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Market for Pressure Ulcer Care Solutions in Japan

Updated Category News Views 184

Growth of the Pressure Ulcer Care Dressing Market in Japan The Japan pressure ulcer care dressing market is expected to surge significantly, with forecasts predicting a market valuation exceeding US$ 226.75 million by 2032. This marks a substantial increase from the US$ 129.68 million recorded in 2023, reflecting a compound annual growth rate (CAGR) of 6.52% during the...

Continue Reading
Harnessing Innovation: RS Transforms Discrete Manufacturing

Updated Category News Views 135

Harnessing Innovation in Discrete Manufacturing Whether your business is at the beginning stages of digital transformation or is already scaling, RS is equipped with the products and expertise necessary to implement smart solutions tailored to your operational needs. RS, a leading global provider of high-service product and service solutions for industrial clients, is...

Continue Reading
Dr. Lu Xianping's Impact on China's Pharmaceutical Innovation

Updated Category News Views 121

Dr. Lu Xianping Receives Prestigious Entrepreneur Award Recently, Dr. Lu Xianping, the Founder and Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, received accolades as the Chinese mainland winner of a prominent entrepreneur award. This recognition is a testament to his commitment to enhancing quality and innovation in the pharmaceutical field. Significance of the...

Continue Reading
Saturna Capital Unveils Enhanced HSA for Muslim Investors

Updated Category News Views 204

Updates to the Shifa Health Savings Account Saturna Capital Corporation has recently enhanced its Shifa Health Savings Account (HSA), tailoring it specifically for the unique needs of Muslim investors. This innovative HSA incorporates Islamic Investment Principles, ensuring it aligns with religious beliefs while meeting the highest standards in the industry. Features of...

Continue Reading
Understanding Cipher Mining's Short Interest and Market Trends

Updated Category News Views 240

What’s Happening with Cipher Mining’s Stock? Cipher Mining's short percentage of float has recently recorded an increase of 19.77%. The company now reports a total of 53.60 million shares that have been sold short, representing a significant 20.48% of all shares available for trading. Based on current trading volumes, traders would require approximately 1.32 days to...

Continue Reading